NCT02691481已完成不适用
Effect of Diabetes-specific Formulas on Glucose Metabolism and GLP-1 Secretion in Patients With Type 2 Diabetes
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 25
- 主要终点
- Glucose area under the curve 0-240 minutes
研究概览
简要总结
Diabetes-specific nutritional formulas (DSNFs) are frequently used as part of medical nutrition therapy for patients with type 2 diabetes in order to improve glycemic control and enhance weight reduction. The mechanism through which DSNFs improve postprandial (PP) plasma glucose is not yet known.
The aim of this study is to compare the effects of 2 DSNFs versus oatmeal on PP plasma glucose, serum insulin and serum active glucagon-like peptide-1 (GLP-1), serum free fatty acids (FFA) and serum triglycerides (TG).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with type 2 diabetes treated with oral diabetes medications
排除标准
- •Type 1 diabetes
结局指标
主要结局
Glucose area under the curve 0-240 minutes
时间窗: 240 minutes
次要结局
未报告次要终点
研究者
相似试验
尚未招募
不适用
Effect of Diabetes-Specific Nutrition Formula on the Metabolic Parameters of Filipino Adults with Metabolic SyndromeMetabolic SyndromeNCT06729008St. Luke's Medical Center, Philippines35
已完成
不适用
Efficacy and Safety of Diabetes-specific Formula in Patients With Type 2 Diabetes MellitusDiabetes Mellitus, Type 2NCT04622722Société des Produits Nestlé (SPN)30
终止
4 期
Enteral Nutrition and Glycemic Variability Neurological Intensive Care Unit StudyIschemic StrokesSubarachnoid HemorrhageSubdural HematomaIntracranial HemorrhageNCT01463878Eastern Virginia Medical School14
已完成
不适用
Hyperglycemia in Patients with Stroke and Indication of Enteral NutritionHyperglycaemia (Non Diabetic)Enteral Feeding IntoleranceStrokeNCT03422900Endocrinology and Clinical Nutrition Research Center, Spain52
招募中
2 期
Efficacy of using diabetic specific formula as a meal replacement to control blood sugar levelpatients with type 2 diabetes more than 6 months and receiving behavioral modification treatment and or receiving Use of diabetes medication without any change in medication during the 3-month period before the study.1.type 2 diabetes 2.Meal replacementTCTR20230122001Faculty of Madicine, Thammasat University154